Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H17N4OS.NO3 |
Molecular Weight | 327.361 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1c(CCO)sc[n+]1Cc2cnc(C)[nH]c2=N.N(=O)(=O)[O-]
InChI
InChIKey=UIERGBJEBXXIGO-UHFFFAOYSA-N
InChI=1S/C12H17N4OS.NO3/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;2-1(3)4/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);/q+1;-1
Molecular Formula | C12H17N4OS |
Molecular Weight | 265.3561 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | NO3 |
Molecular Weight | 62.0049 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine
pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7120152
Curator's Comment:: The transport of thiamine across the blood brain barrier was shown in rats.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9H3S4 Gene ID: 27010.0 Gene Symbol: TPK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16550223 |
|||
Target ID: GO:0005975 |
|||
Target ID: WP408 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | M.V.I.-12 Approved UseM.V.I.-12 Unit Vial, is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition. Launch Date-5.32137607E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
386 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
40 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
95 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
39 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
397 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
113 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2046 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
214 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
623 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
177 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2059 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
612 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305197/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
THIAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes | |||
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://go.drugbank.com/drugs/DB00152 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Thiamine for Alzheimer's disease. | 2001 |
|
[Evaluation of vitamin and immune status of patients with chronic palatal tonsillitis]. | 2001 |
|
Effects of vitamins on hepatic nuclear binding of L-tryptophan. | 2001 |
|
Influence of a probiotic yoghurt on the status of vitamins B(1), B(2) and B(6) in the healthy adult human. | 2001 |
|
Rapid diagnosis of alcoholic ketoacidosis by proton NMR. | 2001 Apr |
|
Do breastfed infants need supplemental vitamins? | 2001 Apr |
|
Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. | 2001 Apr |
|
The multifaceted and widespread pathology of magnesium deficiency. | 2001 Feb |
|
Aroma extract dilution analysis of a beeflike process flavor from extruded enzyme-hydrolyzed soybean protein. | 2001 Feb |
|
Wernicke's encephalopathy following gastroplasty for morbid obesity. | 2001 Feb |
|
Evidence for non-enzymatic glycosylation in Escherichia coli. | 2001 Feb |
|
Lactic acidosis update for critical care clinicians. | 2001 Feb |
|
Neurotoxicity and neurocognitive impairments with alcohol and drug-use disorders: potential roles in addiction and recovery. | 2001 Feb |
|
Consequences of a modified putative substrate-activation site on catalysis by yeast pyruvate decarboxylase. | 2001 Feb 13 |
|
Inhibitors of advanced glycation end product-associated protein cross-linking. | 2001 Feb 14 |
|
Reaction mechanism for mammalian pyruvate dehydrogenase using natural lipoyl domain substrates. | 2001 Feb 15 |
|
Glucose induced IEG expression in the thiamin-deficient rat brain. | 2001 Feb 16 |
|
Certification of B-group vitamins (B1, B2, B6, and B12) in four food reference materials. | 2001 Jan |
|
Longitudinal vitamin and homocysteine levels in normal pregnancy. | 2001 Jan |
|
Nutritional evaluation of some processed catering foods. | 2001 Jan |
|
[Unusual MR findings of Wernicke encephalopathy with cortical involvement]. | 2001 Jan |
|
Phylogenetic analyses and comparative genomics of vitamin B6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways. | 2001 Jan |
|
Manothermosonication of foods and food-resembling systems: effect on nutrient content and nonenzymatic browning. | 2001 Jan |
|
Sorption and desorption studies on chitin gels. | 2001 Jan 10 |
|
Molecular cloning of human thiamin pyrophosphokinase. | 2001 Jan 26 |
|
Effects of glucose, vitamins, and DO concentrations on pyruvate fermentation using Torulopsis glabrata IFO 0005 with metabolic flux analysis. | 2001 Jan-Feb |
|
Use of vitamin supplements and cataract: the Blue Mountains Eye Study. | 2001 Jul |
|
Low thiamine intake and risk of cataract. | 2001 Jul |
|
Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic epithelial cell line NCM460. | 2001 Jul |
|
Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic. | 2001 Jun |
|
Vitamin B1 and B6 retention in milk after continuous-flow microwave and conventional heating at high temperatures. | 2001 Jun |
|
Slc19a2: cloning and characterization of the murine thiamin transporter cDNA and genomic sequence, the orthologue of the human TRMA gene. | 2001 Jun |
|
Simultaneous determination of thiamine and pyridoxine in pharmaceuticals by using a single flow-through biparameter sensor. | 2001 Jun |
|
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | 2001 Jun |
|
Chronic heart failure and micronutrients. | 2001 Jun 1 |
|
Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. | 2001 Jun 26 |
|
Catalytic acid-base groups in yeast pyruvate decarboxylase. 1. Site-directed mutagenesis and steady-state kinetic studies on the enzyme with the D28A, H114F, H115F, and E477Q substitutions. | 2001 Jun 26 |
|
Relationships between dietary intake and cognitive function level in Korean elderly people. | 2001 Mar |
|
Simultaneous determination of thiamin and riboflavin in mushrooms by liquid chromatography. | 2001 Mar |
|
Comparison of a self-administered quantitative food amount frequency questionnaire with 4-day estimated food records. | 2001 Mar |
|
[Isolation, purification and properties of acetolactate synthase from cultured Lactococcus lactis]. | 2001 Mar-Apr |
|
The value of oral thiamine. | 2001 Mar-Apr |
|
[Other drugs administered with TPN solution]. | 2001 May |
|
[Metabolic acidosis induced by TPN]. | 2001 May |
|
The application of capillary electrophoresis to the analysis of vitamins in food and beverages. | 2001 May |
|
Early recognition of acute cardiovascular beriberi by interpretation of hemodynamics. | 2001 May |
|
The bio operon on the acquired symbiosis island of Mesorhizobium sp. strain R7A includes a novel gene involved in pimeloyl-CoA synthesis. | 2001 May |
|
The use of thiamine and thiamine antagonists to investigate the etiology of early mortality syndrome in lake trout (Salvelinus namaycush). | 2001 May |
|
Examination of donor substrate conversion in yeast transketolase. | 2001 May 11 |
|
The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA. | 2001 Sep 7 |
Patents
Sample Use Guides
The starting dose (as a component of M.V.I.–12) is one 10 mL daily dose added directly to an intravenous fluid.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10516094
Human Caco-2 cells were incubated (37 Celsius) in Krebs-Ringer buffer (pH 7.4) for different periods of time in the presence of 0.1 uM and 10 uM thiamine. The uptake study demonstrated that thiamine is transported across the cell membrane with Michaelis-Menten constant of 3.18 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:12:16 UTC 2021
by
admin
on
Fri Jun 25 21:12:16 UTC 2021
|
Record UNII |
8K0I04919X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
2833 (Number of products:2062)
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
||
|
CFR |
21 CFR 184.1878
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
||
|
NCI_THESAURUS |
C45812
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
THIAMINE MONONITRATE
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odour, slight and characteristic. Solubility: Sparingly soluble in water; very slightly soluble in ethanol (~750 g/l) TS. Category: Component of vitamin B. Storage: Thiamine mononitrate should be kept in a tightly closed, non-metallic container, protected from light. Additional information: Even in the absence of light, Thiamine mononitrate is gradually degraded on exposure to a humidatmosphere, the decomposition being faster at higher temperatures. Definition: Thiamine mononitrate contains not less than 98.0% and not more than 101.0% of C12H17N5O4S, calculated with reference to the dried substance. | ||
|
8K0I04919X
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
10456
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | RxNorm | ||
|
10762
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
DBSALT001495
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
CHEMBL1547
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
208-537-4
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
532-43-4
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
SUB12366MIG
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
M10717
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | Merck Index | ||
|
C87669
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY | |||
|
532-43-4
Created by
admin on Fri Jun 25 21:12:16 UTC 2021 , Edited by admin on Fri Jun 25 21:12:16 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |